Compare Freeport-McMoRan Inc (FCX) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Freeport-McMoRan Inc vs Spyre Therapeutics Inc. Common Stock — how do they compare? Freeport-McMoRan Inc trades at $68.72 (market cap $104.00B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Freeport-McMoRan Inc is far larger — about 13.8× Spyre Therapeutics Inc. Common Stock's market cap, and Freeport-McMoRan Inc pays a 0.83% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Freeport-McMoRan Inc for 70 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| FCX | SYRE | |
|---|---|---|
Market Cap | $104.00B | $7.52B |
Volume | 7,316,762 | 1,441,031 |
Sector | Basic Materials | Health |
52-Week High | $79.91 | $108.92 |
52-Week Low | $38.65 | $22.18 |
Typical Hold Time | 70 Days | 0 Days |
Enterprise Value | $110.28B | $6.52B |
Dividend Yield | 0.83% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FCX trades at $72.42, down 1.19% today, with a bullish technical signal from moving averages and a consensus analyst price target of $73.50. The company has beaten earnings estimates for the last three quarters, with Q3 2026 results pending. Revenue reached $25.92B in 2025, and net income margin improved to 11.38%. Strong cash flow from operations of $5.61B supports dividend payments and growth projects amid rising copper demand driven by AI and data centers.
FCX presents a positive outlook with robust fundamentals and favorable copper market dynamics, but faces risks from cost pressures and regulatory scrutiny. Earnings growth and expansion initiatives are key catalysts, while investor sentiment remains bullish based on analyst ratings.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Freeport-McMoRan Inc
Freeport-McMoRan Inc is an international mining company. It operates geographically diverse assets with proven and probable mineral reserves of copper, gold and molybdenum. The company's portfolio of assets includes the Grasberg minerals district in Indonesia
Read more on FCX →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
